3.925
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SLDB Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$3.50
Aprire:
$3.5
Volume 24 ore:
1.51M
Relative Volume:
1.03
Capitalizzazione di mercato:
$303.88M
Reddito:
$14.79M
Utile/perdita netta:
$-102.44M
Rapporto P/E:
-1.2911
EPS:
-3.04
Flusso di cassa netto:
$-91.73M
1 W Prestazione:
+20.40%
1M Prestazione:
-8.93%
6M Prestazione:
-24.23%
1 anno Prestazione:
-50.00%
Solid Biosciences Inc Stock (SLDB) Company Profile
Nome
Solid Biosciences Inc
Settore
Industria
Telefono
617-337-4680
Indirizzo
500 RUTHERFORD AVENUE, CHARLESTOWN, MA
Confronta SLDB con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
SLDB
Solid Biosciences Inc
|
3.92 | 235.65M | 14.79M | -102.44M | -91.73M | -3.04 |
![]()
ONC
Beone Medicines Ltd Adr
|
257.64 | 26.01B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
447.78 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.3499 | 40.54M | 0 | 0 | 0 | 0.00 |
![]()
VRNA
Verona Pharma Plc Adr
|
84.75 | 6.29B | 0 | -153.72M | -103.81M | -2.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
485.21 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Solid Biosciences Inc Stock (SLDB) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-01-08 | Iniziato | Truist | Buy |
2024-12-13 | Iniziato | Wedbush | Outperform |
2024-12-10 | Iniziato | JMP Securities | Mkt Outperform |
2024-07-15 | Aggiornamento | JP Morgan | Neutral → Overweight |
2024-06-24 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
2024-05-31 | Ripresa | Piper Sandler | Overweight |
2024-03-28 | Iniziato | William Blair | Outperform |
2024-03-15 | Iniziato | Citigroup | Buy |
2024-03-14 | Aggiornamento | Piper Sandler | Neutral → Overweight |
2023-12-08 | Iniziato | H.C. Wainwright | Buy |
2021-07-12 | Iniziato | Piper Sandler | Neutral |
2021-05-27 | Iniziato | Jefferies | Buy |
2021-03-16 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
2021-03-09 | Iniziato | Barclays | Overweight |
2021-01-08 | Aggiornamento | Credit Suisse | Underperform → Neutral |
2020-07-28 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
2020-05-07 | Downgrade | Evercore ISI | Outperform → In-line |
2019-10-11 | Iniziato | Evercore ISI | Outperform |
2019-08-29 | Downgrade | Citigroup | Neutral → Sell |
2019-08-19 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
2019-08-16 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
2019-05-14 | Downgrade | Credit Suisse | Neutral → Underperform |
2019-05-14 | Downgrade | Goldman | Neutral → Sell |
2019-02-08 | Aggiornamento | Citigroup | Sell → Neutral |
2019-02-08 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
2018-11-06 | Iniziato | Citigroup | Sell |
2018-09-06 | Iniziato | Credit Suisse | Neutral |
Mostra tutto
Solid Biosciences Inc Borsa (SLDB) Ultime notizie
Solid Biosciences (SLDB) Announces Stock Grants Under Inducement Plan | SLDB Stock News - GuruFocus
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Solid Biosciences Awards Strategic RSU Grants: New Hires Receive 34,550 Shares Under Nasdaq Compensation Rule - Stock Titan
Millennium Management LLC Sells 397,321 Shares of Solid Biosciences Inc. (NASDAQ:SLDB) - Defense World
Northern Trust Corp Has $676,000 Stake in Solid Biosciences Inc. (NASDAQ:SLDB) - Defense World
Solid Biosciences Reports Increased Loss Amid R&D Expansion - TipRanks
BNP Paribas Financial Markets Acquires New Holdings in Solid Biosciences Inc. (NASDAQ:SLDB) - Defense World
D. E. Shaw & Co. Inc. Buys Shares of 51,972 Solid Biosciences Inc. (NASDAQ:SLDB) - Defense World
Solid Biosciences to Participate at the Jefferies Global Healthcare Conference - The Manila Times
Solid Biosciences Leadership Team to Reveal Latest Genetic Medicine Strategy at Major Healthcare Conference - Stock Titan
Solid Biosciences Inc. (NASDAQ:SLDB) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Solid Biosciences’ SWOT analysis: gene therapy stock poised for potential breakthrough - Investing.com Nigeria
Research Analysts Set Expectations for SLDB FY2025 Earnings - Defense World
Solid Biosciences (SLDB) Receives Overweight Rating by Cantor Fi - GuruFocus
Solid Biosciences (SLDB) Receives Overweight Rating by Cantor Fitzgerald | SLDB Stock News - GuruFocus
Solid Biosciences (NASDAQ:SLDB) Given New $15.00 Price Target at Chardan Capital - Defense World
Solid Biosciences (SLDB) Maintains Buy Rating Amid Revised Price Target | SLDB Stock News - GuruFocus
Chardan Adjusts Price Target on Solid Biosciences to $15 From $16, Maintains Buy Rating - marketscreener.com
Q1 Earnings Forecast for SLDB Issued By William Blair - Defense World
Wedbush Issues Pessimistic Forecast for Solid Biosciences (NASDAQ:SLDB) Stock Price - Defense World
We Think Solid Biosciences (NASDAQ:SLDB) Can Afford To Drive Business Growth - Yahoo Finance
Solid Biosciences (SLDB) Maintains Overweight Rating Amid Price Target Adjustment | SLDB Stock News - GuruFocus
Solid Biosciences (SLDB) Sees Price Target Cut by Piper Sandler Amid Trial Updates | SLDB Stock News - GuruFocus
SLDB: Piper Sandler Lowers Price Target for Solid Biosciences | SLDB Stock News - GuruFocus
Truist maintains buy on Solid Biosciences stock, price target at $16 - Investing.com
Solid Biosciences (SLDB) Target Price Updated by Wedbush Analyst - GuruFocus
Solid Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Solid Biosciences (SLDB) Target Price Revised Amid Share Count Changes | SLDB Stock News - GuruFocus
Wedbush Cuts Price Target on Solid Biosciences to $17 From $18, Keeps Outperform Rating - marketscreener.com
Solid Biosciences: Promising Gene Therapy Advancements and Strategic Initiatives Drive Buy Rating - TipRanks
Barclays Adjusts Price Target for Solid Biosciences (SLDB) Amid Progress | SLDB Stock News - GuruFocus
Solid Biosciences Files $400 Million Mixed Shelf - marketscreener.com
Solid Biosciences Files Prospectus for $85 Million Offering - TipRanks
SLDB Shows Promise with Early Results in Duchenne Muscular Dystrophy Trial | SLDB Stock News - GuruFocus
Solid Biosciences (SLDB) Files for $400 Million Mixed Securities Shelf | SLDB Stock News - GuruFocus
Solid Biosciences Inc Files For Mixed Shelf Of Up To $400 Million - marketscreener.com
Form 424B5 Solid Biosciences Inc. - StreetInsider
Solid Biosciences Reports First Quarter 2025 Financial Results a - GuruFocus
Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates | SLDB Stock News - GuruFocus
Solid Biosciences Provides Business Update and Financial Results for Q1 2025, Advances Gene Therapy Programs for Duchenne Muscular Dystrophy, Friedreich's Ataxia, and CPVT - Nasdaq
Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates - GlobeNewswire
Solid Biosciences Reports Breakthrough in Duchenne Treatment: Q1 Results Reveal Strong Pipeline Progress - Stock Titan
Solid Biosciences (SLDB) Expected to Announce Earnings on Wednesday - Defense World
Partner With Us - Solid Biosciences
Solid Biosciences Reports Quarterly Loss Per Share Of $0.54 - Reuters
Analysts Have Conflicting Sentiments on These Healthcare Companies: Axsome Therapeutics (AXSM), Premier (PINC) and Solid Biosciences (SLDB) - The Globe and Mail
Invesco Ltd. Invests $49,000 in Solid Biosciences Inc. (NASDAQ:SLDB) - Defense World
Solid Biosciences Expands Team: 81,000 RSUs Awarded to 7 Strategic New Hires - Stock Titan
Solid Biosciences to Participate at The Citizens Life Sciences Conference - The Manila Times
Exclusive: Solid Biosciences CEO Ready to Reveal Latest Company Vision at Major Life Sciences Event - Stock Titan
Solid Biosciences to Present at the American Society of Gene and Cell Therapy's 28th Annual Meeting - The Manila Times
Solid Biosciences Inc Azioni (SLDB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Solid Biosciences Inc Azioni (SLDB) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
Bain Capital Life Sciences Inv | 10% Owner |
Feb 19 '25 |
Buy |
4.03 |
1,000,000 |
4,030,000 |
5,034,582 |
PERCEPTIVE ADVISORS LLC | Director |
Feb 19 '25 |
Buy |
4.03 |
5,000,000 |
20,150,000 |
11,833,539 |
Adage Capital Management, L.P. | 10% Owner |
Feb 18 '25 |
Buy |
7.56 |
252,545 |
1,909,240 |
4,248,084 |
Hanrahan Jessie | Chief Regulatory Officer |
Feb 14 '25 |
Sale |
3.96 |
3,079 |
12,193 |
19,281 |
Brooks Gabriel | Chief Medical Officer |
Feb 14 '25 |
Sale |
3.96 |
3,256 |
12,894 |
22,812 |
Tan Kevin | CFO & Treasurer |
Feb 14 '25 |
Sale |
3.96 |
3,164 |
12,529 |
32,250 |
Howton David T | Chief Operating Officer |
Feb 14 '25 |
Sale |
3.96 |
5,561 |
22,022 |
24,789 |
Herzich Paul | Chief Technology Officer |
Feb 14 '25 |
Sale |
3.96 |
2,688 |
10,644 |
18,388 |
Cumbo Alexander | President and CEO |
Feb 14 '25 |
Sale |
3.96 |
11,365 |
45,005 |
60,717 |
Ganot Ilan | Director |
Feb 14 '25 |
Sale |
3.96 |
1,711 |
6,776 |
14,839 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):